Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple negative breast cancer (TNBC) – <br />Results from GeparSixto<br /><br />Gunter von Minckwitz, Eric Hahnen, Peter A. Fasching, Jan Hauke, Andreas Schneeweiss, Christoph T. Salat, Mahdi Rezai, Jens U.
Blohmer, Dirk M. Zahm, Christian Jackisch, Bernd Gerber, Peter Klare, Sherko Kümmel, Holger Eidtmann, Stephan Paepke, Valentina Nekljudova, Sibylle Loibl, Michael Untch, Rita Schmutzler <br />for the <br />GBG/AGO-B study groups<br />
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
Introduction
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
Slide 3
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
Slide 4
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
Selected Objectives
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
Key Eligibility Criteria
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
pCR Rates (ypT0 ypN0) <br />
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
Slide 8
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
Characteristics of patients with TNBC
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
pCR Rates (%) in Patients with TNBC
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
Slide 11
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
pCR (ypT0 ypN0) <br />in all Patients with TNBC
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
pCR (ypT0/is ypN0) <br />in all Patients with TNBC
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
Prediction of Carboplatin Effect on pCR
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
Summary
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
Conclusion
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting
Acknowledgements
Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting